Stereotactic body radiation therapy or SBRT (sometimes referred to as SABR or SHARP or CyberKnife) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: body, intermediate, low, radiation, risk, SBRT, sterotactic | 10 Comments »
A clinical research team from the Mayo Clinic (Routman et al.) has reported 10-year oncological results on 974 consecutive low- and intermediate-risk patients treated with low-dose-rate brachytherapy monotherapy (using iodine-125 seeds) from 1998 to 2013. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachytherapy, intermediate, low, low-dose-rate, monotherapy, outcome, risk, seeds | 3 Comments »
We have known for some time that taking abiraterone acetate (Zytiga) with food (as opposed to on an empty stomach) might well allow patients to be able to take significantly lower doses of this product and gain the same clinical benefit as is currently known to be beneficial from taking 1,000 mg/day when fasting. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, dose, food, low, standard, with, without | 5 Comments »
It is now clear that men who meet NCCN criteria for very low- and low-risk forms of prostate cancer are almost invariably good candidates for initial management on active surveillance (i.e., just monitoring as opposed to immediate treatment). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, favorab le, intermediate, low, outcome, risk, surveillance, unfavorable | 8 Comments »
It has been hypothesized for some time that men diagnosed with a low PSA level (i.e., < 4.0 ng/ml) but a high Gleason score (of 8, 9, or 10) are at elevated risk for more advanced disease and a shorter survival time than some others. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Gleason, high, low, PSA, risk, score, survival | 4 Comments »
A paper to be presented this Thursday at the upcoming Genitourinary Cancers Symposium in Orlando, Florida, will clearly confirm the above heading, which should come as no surprise to anyone. The issue has always been whether there is a subset of men with (“favorable”) intermediate-risk disease who are potentially appropriate candidates. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, intermediate, low, outcomes, risk, surveillance | 4 Comments »
According to a media release issued last Thursday, a paper presented at a cancer conference in Anaheim, California, last week suggests that men with prostate cancer who drank green tea every day day prior to having a radical prostatectomy had a significant reduction in markers for prostate inflammation. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: green tea, low, progression, risk | 3 Comments »
In a newly published article in the American Journal of Clinical Oncology, Mishra et al. have attempted to assess the application of immediate, first-line treatment among older men with favorable-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, decision, elderly, low, risk, Treatment, very lw | Leave a comment »
A new study has attempted to calculate the impact of age, health status, and patient preference on the relative outcomes (and merits) of immediate surgery as compared to active surveillance for the management of low-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, life, low, outcome, quality, risk, surgery | 4 Comments »
The need for patients diagnosed with early stage prostate cancer to be highly involved in the decision as to which form of management they wish to be given is well understood. However, there has been a relative dearth of data on why patients actually make their individual decisions. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: choice, first line, intermediate, localized, low, Management, patient, risk, Treatment | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 